Identification of Allergen-reactive Antibodies in the Blood of Pollen Allergic Patients

• Conditions: Pollen Allergy

• Registration Number: NCT03727399
• Lead Sponsor: Mabylon AG

Brief Summary

The project examines the hypothesis that monoclonal allergen-neutralizing antibodies can be recombinantly produced from B lymphocytes isolated from pollen allergic patients. Patient samples suitable for antibody cloning are selected based on seroprofiling for the respective allergens. The study aims at isolating lymphocytes from patients with potential allergen-neutralizing IgG in serum and to clone antibodies from antibody gene sequences obtained from B cells of those patients.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-10-01
• Study First Submitted: 2018-10-31
• Study First Submitted QC: 2018-10-31
• Study First Posted: 2018-11-01
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-29
• Last Update Posted: 2025-05-02
• Primary Completion: 2025-12-31
• Study Completion: 2025-12-31

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• History of allergic rhinitis, conjunctivitis or asthma due to sensitization to grass- or birch Allergens
• Male or female patients older than 18 years
• Written informed consent for providing blood and also to allow experimental manipulation

Exclusion Criteria

• Age < 18 years
• Any corticosteroids within the last three days
• Oral corticosteroid therapy within the last ten days
• Parenteral depot corticosteroids within the last three months

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Antibody profiling	October 2018 - September 2021	Analysis and IgG profiling of specific antibodies binding major grass- and tree-pollen allergens in allergic patients.

Trial Locations

Locations (1)

Immunologie Zentrum Zürich; 🇨🇭 Zürich, Switzerland